At an old biscuit factory in South London, giant mixers and industrial ovens have been replaced by robotic arms, incubators, and DNA sequencing machines. James Field and his company LabGenius aren't making sweet treats; they're cooking up a revolutionary, AI-powered approach to engineering new medical antibodies. In nature, antibodies are the body's response to disease and serve as the immune system's front-line troops. They're strands of protein that are specially shaped to stick to foreign invaders so that they can be flushed from the system. Since the 1980s, pharmaceutical companies have been making synthetic antibodies to treat diseases like cancer, and to reduce the chance of transplanted organs being rejected. But designing these antibodies is a slow process for humans--protein designers must wade through the millions of potential combinations of amino acids to find the ones that will fold together in exactly the right way, and then test them all experimentally, tweaking some variables to improve some characteristics of the treatment while hoping that doesn't make it worse in other ways.

Researchers have developed a new algorithm for clinical use. It is based on artificial intelligence and compares the cells of sick individuals with a reference atlas of healthy cells. In practice, doctors can use it to accurately identify diseased cells. This is a major advantage for personalized medicine. The Human Cell Atlas is the world's largest, continuously growing single-cell reference atlas.

Since the 1980's, human/machine interactions, and human-in-the-loop (HTL) scenarios in particular, have been systematically studied. It was often predicted that with an increase in automation, less human-machine interaction would be needed over time. Human input is still relied upon for most common forms of AI/ML training, and often even more human insight is required than ever before. As AI/ML evolves and baseline accuracy of models improves, the type of human interaction required will change from creation of generalized ground truth from scratch, to human review of the worst-performing ML predictions in order to improve and fine-tune models iteratively and cost-effectively. Deep learning algorithms thrive on labeled data and can be improved progressively if more training data is added over time.

A new artificial intelligence could help sort normal cells from diseased cells, researchers report in a new study. The Human Cell Atlas is a deep learning algorithm method that uses single-cell RNA sequencing to distinguish activated and deactivated cells within humans at any point, according to a study published Wednesday in Nature Communications. The ability to pinpoint healthy cells from diseased cells at a given time within a person's life cycle. "From a methodological point of view, this represents an enormous leap forward. Previously, such data could only be obtained from large groups of cells because the measurements required so much RNA," Maren Büttner, a researcher at the Institute of Computational Biology of the Helmholtz Zentrum München, said in a news release.

Meteorologists can now reliably tell us if it is going to rain tomorrow, but wouldn't dream of forecasting rain a year from now. Similarly, scientists find it much easier to predict what the world will look like in the next decade rather than in a century. This is because the technology of tomorrow relies on the science of today – it is only after we have understood a certain concept that we can think about how to put it to use. A famous example is Michael Faraday's research into electricity and magnetism in the 1830s. It was only decades later that others saw how to use this new knowledge to build electric motors and power generators, inventions that transformed our world.

The company is best known for its computers and phones. But Microsoft is now setting its sights on one of the most important questions in science - how to cure cancer. One of its research labs aims to tackle the disease as if it were a bug in a computer system, with the hopes of being able to make cells into living computers that can'reprogramme' cancer cells within the decade. Microsoft is now setting its sights on one of the most important questions in science - how to cure cancer. The company aims to use a computer code to treat the disease like a computer virus, 'reprogramme' diseased cells.